Rapidscan Pharma Solutions EU (RPS) has come to an agreement with GE Healthcare to promote and distribute Rapiscan (regadenoson) in the UK and Germany.
Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).
Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication.
Stephen Lightfoot, global MI-SPECT segment leader, Medical Diagnostics, GE Healthcare, said: "The opportunity to launch Rapiscan with Rapidscan Pharma Solutions EU leverages the expertise and unique capabilities of both organisations - to bring an important product used for the diagnosis of coronary artery disease to the UK and German marketplace."
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...